Table 3.

Liver fatty acid binding protein immunohistochemistry

Staining pattern	None (<1%)	Focal/patchy (<80%)	Diffuse (≥80%)
N	18 (24.3%)	24 (32.4%)	32 (43.2%)
Age (year)	18–80 (median 67.5)	38 – 79 (median 65)	26–83 (median 66)
Male: Female	12:6	17:7	15:17
Viral hepatitis or alcoholic liver disease	0	4	1
Diabetes mellitus	2/13 (15.4%)	7/19 (36.8%)	7/29 (24.1%)
Body mass index (available n)	13	17	24
< 25	6 (46.2%)	3 (17.6%)	10 (41.7%)
25 – 29	5 (38.5%)	6 (35.3%)	7 (29.2%)
≥ 30	2 (15.4%)	8 (47.1%)	7 (29.2%)
Metabolic Syndrome	5/6 (83.3%)	3/7 (42.3%)	7/13 (53.8%)
Size (cm)	1.3 – 24 (mean 9.8)	2.2 – 15 (mean 8.0)	1.5 – 17 (mean 7.2)
Multifocality	8 (44.4%)	4 (16.7%)	8 (25.0%)
Tumor Grade* (p< 0.05 when comparing grades I+II and III+IV)	I: 2 (11.1%),	I: 2 (8.3%),	I: 6 (18.8%),
	II: 7 (38.9%),	II: 9 (37.5%),	II: 19 (59.4%),
	III: 5 (27.8%),	III: 8 (33.3%),	III: 4 (12.5%),
	IV: 4 (22.2%)	IV: 5 (20.8%)	IV: 3 (9.4%)
Steatosis (tumor)	2 (11.1%)	2 (8.3%)	8 (25.0%)
Steatosis (non-tumor liver)	3 (16.7%)	6 (25.0%)	6 (18.8%)
Fibrosis	0: 5 (27.8%),	0: 5 (20.8%),	0: 10 (31.3%),
	1: 4 (22.2%),	1: 8 (33.3%),	1: 7 (21.9%),
	2: 8 (44.4%)	2: 6 (25.0%),	2: 13 (40.6%),
	3: 1 (5.6%)	3: 5 (20.8%)	3: 2 (6.3%)

^*p < 0.05.